Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live Bifidobacterium
- Development stage
- Unknown
- Lead developer
- Renji Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Live Bifidobacterium refers to pharmaceutical-grade probiotic preparations containing viable bacteria of the genus *Bifidobacterium*, most commonly *Bifidobacterium longum*, *Bifidobacterium infantis*, or *Bifidobacterium breve*. These products are classified as live biotherapeutic products (LBPs) and are primarily used to manage gastrointestinal disorders by restoring a healthy balance to the intestinal microbiota. In clinical practice, particularly in China, live Bifidobacterium capsules are utilized as an adjuvant therapy for inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease. The bacteria exert their therapeutic effects by competing with pathogenic microorganisms for nutrients and adhesion sites, strengthening the intestinal epithelial barrier, and modulating the host's immune system to reduce the production of pro-inflammatory cytokines while promoting anti-inflammatory responses.
- Brand names
- Baisangle
- Other names
- BifidobacteriumBifidobacterium longumBifidobacterium infantisBifidobacterium breveprobiotic Bifidobacterium
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on live Bifidobacterium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live Bifidobacterium.